[2]
Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer biomarkers discovery and validation: State of the art, problems and future perspectives. Adv Exp Med Biol 2015; 867: 9-26.
[3]
Gnjatic S, Bronte V, Brunet L, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J ImmunoTherapy Cancer 2017; 5(1)
[4]
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24: 26.
[5]
Herbst R, Baas P, Kim D, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 2016; 387(10027): 1540-50.
[6]
Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists: A perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 2016; 140(4): 341-4.
[7]
Le D, Uram J, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 2015; 372(26): 2509-20.
[8]
Le D, Durham J, Smith K, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357(6349): 409-13.
[9]
Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25(3): 611-8.
[10]
Cesano A, Warren S. Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines 2018; 6(1): 14.
[11]
Sheerens H, Malong A, Bassett K, et al. Current status of companion and complementary diagnostics: Strategic considerations for development and launch. Trends Pharmacol Sci 2017; 10(2): 84-92.
[12]
Beaver J, Tzou A, Blumenthal G, et al. An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin Cancer Res 2016; 23(6): 1368-72.
[13]
Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The challenge for development of valuable immune-oncology biomarkers. Clin Cancer Res 2017; 23(17): 4970-9.
[14]
Zaretsky JM, Garcia-Diaz A, Shin DS, et al.
Mutations Associated
with Acquired Resistance to PD-1 Blockade in Melanoma. ;
N Engl
J Med 2016. 1;375(9): 819-29.
[15]
Hirsch F, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017; 12(2): 208-22.
[16]
Rimm DL.
A prospective, multi-institutional, pathologist-based
assessment of 4 immunohistochemistry assays for PD-L1 expression
in non-small cell lung cancer. JAMA Oncology 2017; 1; 3(8):
1051-58.
[17]
Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol 2016; 11(11): 1846-55.
[18]
Ferreira CG, Melo AC, Stefani S, et al. Increasing access to immuno-oncology therapies in brazil. J Cancer Policy 2018; 16: 1-5.
[19]
Baik C, Rubin E, Forde P, et al. Immuno-oncology clinical trial design: limitations, challenges and opportunities. Clin Cancer Res 2017; 23: 4992-5002.
